Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors

NCT00003750 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00003750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2001
Completion date
September 30, 2005
Enrollment
28 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin), neuroblastoma, sarcoma, unspecified childhood solid tumor, protocol specific